Full Press Release Details
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome.
IONS
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome
Key Takeaway: Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome